EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tuberculosis: An Update for the Clinician

Saskia Janssen iD, Melissa Murphy, Caryn Upton, Brian Allwood, Andreas H Diacon

Respirology · 2025-03 · 30 (3) · 196-205

DOI: 10.1111/resp.14887 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Respirology, online erschienen am 31.01.2025. Verfasst von Saskia Janssen und 4 weiteren Autor:innen. Beteiligte Einrichtung: TASK, Cape Town, South Africa. Hauptthemen laut MEDLINE: Tuberculosis. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon Europe Marie Sklodowska-Curie Actions Personal Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB) remains a significant global health threat with high mortality and efforts to meet WHO End TB Strategy milestones are off‐track. It has become clear that TB is not a dichotomous infection with latent and active forms but presents along a disease spectrum. Subclinical TB plays a larger role in transmission than previously thought. Aerosol studies have shown that undiagnosed TB patients, even with paucibacillary disease, can be highly infectious and significantly contribute to TB spread. Encouraging clinical results have been seen with the M72/AS01 E vaccine. If preliminary results can be confirmed in ongoing larger trials, modelling shows the vaccine can positively impact the epidemic. TB preventive therapy (TPT), especially for high‐risk groups like people living with HIV and household contacts of drug‐resistant TB patients, has shown efficacy but implementation is resource intensive. Treatment options for infectious patients have grown rapidly. New shorter, all‐oral treatment regimens represent a breakthrough, but progress is threatened by rising resistance to bedaquiline. Many new chemical entities are entering clinical trials and raise hopes for all‐new regimens that could overcome rising resistance rates to conventional agents. More research is needed on the management of complex cases, such as central nervous system TB and severe HIV‐associated TB. Post‐TB lung disease (PTLD) is an under‐recognised but growing concern, affecting millions of survivors with lasting respiratory impairment and increased mortality. Continued investment in development of TB vaccines and therapeutics, treatment shortening, and management of TB sequelae is critical to combat this ongoing public health challenge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TuberculosisHumansAntitubercular AgentsTuberculosis Vaccines

Stichwörter der Autor:innen

diagnosticspost‐tuberculosis lung diseasepreventiontreatmenttuberculosis

Substanzen

Antitubercular AgentsTuberculosis Vaccines

Autor:innen und Institutionen

  • TASK, Cape Town, South Africa.
  • Radboud University Medical Center, Nijmegen, the Netherlands.
  • Tygerberg Hospital, Cape Town, South Africa.
  • Division of Pulmonology, Department of Medicine, Stellenbosch University, Cape Town, South Africa.

ORCID-Profile: Saskia Janssen

Förderung

  • Horizon Europe Marie Sklodowska-Curie Actions Personal Fellowship

Zitieren

APA

Janssen, S., Murphy, M., Upton, C., Allwood, B., & Diacon, A. H. (2025). Tuberculosis: An Update for the Clinician. Respirology, 30(3), 196-205. https://doi.org/10.1111/resp.14887

Vancouver

Janssen S, Murphy M, Upton C, Allwood B, Diacon AH. Tuberculosis: An Update for the Clinician. Respirology. 2025;30(3):196-205. doi:10.1111/resp.14887

BibTeX
@article{Janssen2025,
  author = {Janssen, Saskia and Murphy, Melissa and Upton, Caryn and Allwood, Brian and Diacon, Andreas H},
  title = {Tuberculosis: An Update for the Clinician},
  journal = {Respirology},
  year = {2025},
  volume = {30},
  number = {3},
  pages = {196--205},
  doi = {10.1111/resp.14887}
}
Kostenlos starten →